 | Up a level |
Journal Article
Chowdhury, S., Abida, W., Arranz Arija, J., Daugaard, G., Fizazi, K., Gez, E., Heidenreich, A., Joly Lobbedez, F., McDermott, R., Merseburger, A. S., Piulats Rodriguez, J. M., Sautois, B., Sridhar, S., Sternberg, C. N., Watkins, S., Simmons, A., Shetty, S., Golsorkhi, A., Ryan, C. J. and Scher, H. (2017). The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Heidenreich, A., Carl, S., Feyerabend, S., Gleissner, J., Gruellich, C., Heinrich, B., Merseburger, A., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Go, J., Golsorkhi, T., Abida, W. and Scher, H. I. (2018). TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 75 - 76. BASEL: KARGER. ISSN 2296-5262